GL1X · GenesisL1 explorer

Research workbench

Structure of human transthyretin VAL30MET mutant in complex with diflunisal

Analyse Structure of human transthyretin VAL30MET mutant in complex with diflunisal in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
6E73
Type
protein
Length
230 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Transthyretin
UniProt
P02766
Ligands
1FL
Pockets
3 · best druggability 0.33

Structure

x-ray diffraction · 1 distinct chain · 6% helix, 53% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BTransthyretinprotein1156% helix, 53% strandP02766

Ligands and binding sites

  • 1FL · 5-(2,4-difluorophenyl)-2-hydroxy-benzoic acid · ligand · 2 copies · chains A, B
  • ACT · Acetate ion · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
1520.330.7814empty
2640.320.7514empty
3580.310.7616empty

Interfaces

1 interface between chains.

  • A–B · 915 Ų buried · 23 hydrogen bonds · protein-protein

Compared structures

  • 6E73 · Structure of Human Transthyretin Val30Met Mutant in Complex with Diflunisal · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.